Targeted therapy for breast cancer

Bookmark and Share
Published: 22 Apr 2010
Views: 9367
Dr Alison Jones - Dept of Medical Oncology, Royal Free Hospital, London
Dr Jones discusses the use of Trastuzumab (Herceptin) and Lapatinib as drugs to target the HER2 receptor and the possibility of combining these as part of a dual targeting approach, the drawbacks including side effects or resistance among patients and the services offered by HCA.

Click here to see Dr Jones' presentation on dual targeted therapy from EBCC 7